Sendai Virus

Sendai virus, also known as HVJ (Hemaggluting virus of Japan), is a type B parainfluenza virus. Belonging to the genus Paramyxovirus. The Sendai virus has an envelope containing RNA with a molecular weight of 6-7×106, but it is not a template for protein synthesis. Not heat-resistant. Sendai virus is the earliest isolated species in this genus (M. Kuroya). The plasmid is polymorphic with a diameter of 150-600 nanometers. It can agglutinate almost all types of red blood cells and has hemolytic properties. Proliferation occurs in the cytoplasm of cultured cells from chicken embryos and various animal kidneys. Infected cell lines are prone to secondary infections. Due to its ability to fuse various cells, it is widely used for the formation of heterokaryotes and the cultivation of hybrid cells. It is also commonly used for interferon induction along with Newcastle disease virus. This virus is commonly found in mice and pigs, and has also been isolated from humans as a virus that exchanges antigens with Sendai virus (HA2, etc.). The inactivated Sendai virus has no infectivity, but it has antigenicity.

Fig. 1. Schematic diagram of SeV-based hydrogel vaccine (SHV) in preventing tumorigenesis.(Zheng, Bin, et al. 2021)

Introductions

The basic principle of cell fusion technology, which was mainly applied in cell engineering, is that HVJ contains binding sites for cell surface receptors, which can promote the aggregation of different cells and ultimately fuse cell membranes. The site that directly produces this effect is the outer shell of the HVJ virus, not the internal RNA. However, the application of HVJ technology has many drawbacks, such as low cell infection rate, slow fusion speed, high reaction conditions, and difficulty in virus-free fusion Cell fusion technology mainly adopts techniques such as polyethylene glycol (PEG) and electrical stimulation fusion. The clinical trial lasts about one and a half years. After the safety is confirmed, the vaccine may become the first AIDS vaccine put into practical use in the world. In both research and process control, specific reagents play critical roles. For instance, the Sendai Virus (SV) ELISA Kit enables precise quantification of viral particles, aiding in the standardization of fusion protocols and ensuring the removal of infectious virus in final products. Additionally, Anti-Sendai Virus Polyclonal Antibody can be used to confirm viral antigen presence or clearance, monitor immunogenicity, and evaluate the safety of viral-based systems.

Diagnosis

• Molecular testing: Real-time RT-PCR is the most sensitive and specific method, detecting viral RNA in nasal washes, lung tissue, or cell cultures. Commercial kits targeting the N or L gene are available for laboratory use.
• Serological testing: ELISA detects anti-SeV antibodies (IgG/IgM) in sera, useful for surveillance of rodent colonies or retrospective diagnosis of human exposure.
• Virus isolation: SeV can be cultured in various cell lines (e.g., LLC-MK2, Vero cells), with cytopathic effects (CPE) observed as syncytium formation (due to F protein-mediated cell-cell fusion).

Taxonomy and Classification

SeV belongs to the family Paramyxoviridae, which is a group of enveloped RNA viruses that include clinically relevant human pathogens such as measles virus, respiratory syncytial virus (RSV), and human parainfluenza virus (HPIV).

Conclusions

Sendai virus is a multifunctional pathogen and research tool with significance across veterinary science, basic virology, and translational biology. Its well-defined genome, efficient replication cycle, and low pathogenicity in the human body make it a model for studying the biology of paramyxoviruses, as well as a promising carrier for gene therapy and vaccines. Although SeV remains a concern for rodent populations, its biomedical applications are constantly expanding, providing new avenues for treating human diseases. Further research on its molecular mechanism and carrier optimization will unleash more potential in basic science and clinical practice.